First articulated by neurologist Ethan Russo in a 2004 paper in Neuroendocrinology Letters and elaborated in a 2016 review in Cannabis and Cannabinoid Research, the CED hypothesis draws an analogy with other recognised deficiency states , such as serotonin or dopamine dysregulation , in which a neuromodulatory system operating below a functional threshold is proposed to contribute to a cluster of symptoms. The hypothesis is not an accepted clinical diagnosis and does not appear in the DSM-5 or ICD-11.
The endocannabinoid system (ECS) comprises endogenous ligands (principally anandamide and 2-arachidonoylglycerol), their biosynthetic and catabolic enzymes (including FAAH and MAGL), and cannabinoid receptors (primarily CB₁ and CB₂). Under the CED hypothesis, a sustained reduction in endocannabinoid signalling , arising from genetic polymorphisms, chronic stress, dietary insufficiency, or other factors; could theoretically impair ECS-mediated homeostatic functions such as pain modulation, mood regulation, and gastrointestinal motility. These proposed mechanisms remain under active laboratory and preclinical investigation.
Evidence cited in support of the hypothesis includes findings of reduced cerebrospinal fluid anandamide concentrations in certain patient cohorts and animal model data demonstrating heightened nociceptive sensitivity following ECS disruption. Proponents have pointed to conditions including migraine, fibromyalgia, and irritable bowel syndrome as phenotypic candidates. However, the body of human clinical evidence remains limited in sample size and methodological consistency; no validated biomarker for CED has been established, and causal directionality has not been demonstrated. The hypothesis is regarded by the broader research community as speculative pending larger, controlled human studies.
In the Australian regulatory context, no therapeutic product is approved by the Therapeutic Goods Administration (TGA) on the basis of correcting a clinical endocannabinoid deficiency. Any cannabinoid-based medicine available in Australia is accessed under the Poisons Standard scheduling framework (Schedule 4 or Schedule 8, depending on the product) via a prescribing pathway such as the Special Access Scheme (SAS) or Authorised Prescriber scheme, and only for approved indications supported by clinical evidence assessed by the TGA.
Sources: